Pfizer’s gold dust vanishes in Missouri
(Reuters) - A cache of gold dust has gone missing from a Pfizer Inc laboratory in suburban St. Louis, and police say they are investigating whether it was lost or...
Home > Reviews
All Stories
Pfizer’s gold dust vanishes in Missouri
(Reuters) - A cache of gold dust has gone missing from a Pfizer Inc laboratory in suburban St. Louis, and police say they are investigating whether it was lost or...
Human stool treatment upends race to treat colon germ
(Reuters) - Drugmakers racing to develop medicines and vaccines to combat a germ that ravages the gut and kills thousands have a new challenger: the human stool. For patients hit...
Human stool treatment upends race to treat colon germ
(Reuters) - Drugmakers racing to develop medicines and vaccines to combat a germ that ravages the gut and kills thousands have a new challenger: the human stool. For patients hit...
FDA advisory panel backs J&J tuberculosis drug
(Reuters) - An advisory panel to the U.S. Food and Drug Administration on Wednesday voted that an experimental Johnson & Johnson drug for multidrug-resistant tuberculosis appears to be safe and...
FDA advisory panel backs J&J tuberculosis drug
(Reuters) - An advisory panel to the U.S. Food and Drug Administration on Wednesday voted that an experimental Johnson & Johnson drug for multidrug-resistant tuberculosis appears to be safe and...
FDA panel recommends approval of Novo degludec insulin
(Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday voted to recommend approval of Danish drugmaker Novo Nordisk's new ultra-long-acting insulin degludec, despite signals of...
FDA panel recommends approval of Novo degludec insulin
(Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday voted to recommend approval of Danish drugmaker Novo Nordisk's new ultra-long-acting insulin degludec, despite signals of...
Pfizer arthritis drug wins approval, to challenge Humira
(Reuters) - U.S. regulators on Tuesday approved Pfizer Inc's Xeljanz treatment for rheumatoid arthritis, one of the company's most potentially lucrative experimental drugs, which is now poised to compete with...
Pfizer arthritis drug wins approval, to challenge Humira
(Reuters) - U.S. regulators on Tuesday approved Pfizer Inc's Xeljanz treatment for rheumatoid arthritis, one of the company's most potentially lucrative experimental drugs, which is now poised to compete with...